Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of melflufen + daratumumab vs daratumumab in relapsed/refractory multiple myeloma
2019-002161-36Phase 3Terminated
- Sponsor
- Oncopeptides AB
- Start
- Apr 2020
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of melphalan flufenamide in multiple myeloma (MM) (2 arms), sponsored by Oncopeptides AB. Primary endpoint: Progression-free survival. Started Apr 2020; status: terminated.
02
Drugs
melphalan flufenamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2019-002161-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002161-36.